NCT06997068 2026-05-11Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationMayo ClinicPhase 2 Recruiting25 enrolled